NEORAL - SANDIMMUN

 Non-biologic DMARDs in rheumatoid arthritis (excluding methotrexate and leflunomide)

 Azathioprine, sulfasalazine and synthetic antimalarials (hydroxychloroquine, chloroquine) still have a substantial clinical benefit.

Cyclosporine, D-penicillamine, gold salts and tiopronin have no longer a clinical benefit relative to the available alternatives.

• The main focus concerns the following disease-modifying treatments for rheumatoid arthritis (RA):

• azathioprine (IMUREL)
• chloroquine (NIVAQUINE)
• cyclosporine (NEORAL, SANDIMMUN)
• D-penicillamine (TROLOVOL)
• hydroxychloroquine (PLAQUENIL)
• gold salts (ALLOCHRYSINE)
• sulfasalazine (SALAZOPYRINE)
• tiopronin (ACADIONE)

• According to current recommendations, the opinion of the French Society of Rheumatology and the published clinical data, azathioprine, sulfasalazine and synthetic antimalarials (hydroxychloroquine, chloroquine) still have a role in the therapeutic strategy for RA.

• Cyclosporine, D-penicillamine, gold salts and tiopronin no longer have a role in this therapeutic strategies.